Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice

Kishore M. Gadde, Y (Pritham) Raj

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Purpose of Review: This review provides an overview of the current state of drug therapy for obesity, with a focus on four new drug therapies—lorcaserin, phentermine/topiramate, naltrexone/bupropion, and liraglutide 3.0 mg—which have been approved by the US Food and Drug Administration (FDA) for long-term management of obesity since 2012. Topics discussed in this paper include rationale for pharmacotherapy, history of antiobesity drugs, and efficacy and safety data from randomized controlled trials with implications for clinical practice. Recent Findings: Weight loss achieved by currently approved drugs ranges from approximately 3 to 9%, above and beyond weight loss with lifestyle counseling alone, after a year. Response and attrition rates in clinical trials indicate that the benefits of pharmacotherapy range from substantial for some patients, modest for others, and no benefits for others still. Summary: Decisions regarding selection of a suitable drug from the available pharmacotherapy options and duration of treatment should be based on the expected and observed benefit-to-risk balance and tailored to the needs of each individual patient using the principles of shared decision-making.

Original languageEnglish (US)
Article number34
JournalCurrent Diabetes Reports
Volume17
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

Obesity
Clinical Trials
Drug Therapy
Weight Loss
Phentermine
Anti-Obesity Agents
Pharmaceutical Preparations
Bupropion
Naltrexone
United States Food and Drug Administration
Life Style
Counseling
Decision Making
Randomized Controlled Trials
Safety
Therapeutics

Keywords

  • Antiobesity drugs
  • Obesity
  • Overweight
  • Pharmacologic treatment
  • Pharmacotherapy
  • Weight loss medications

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Pharmacotherapy of Obesity : Clinical Trials to Clinical Practice. / Gadde, Kishore M.; Raj, Y (Pritham).

In: Current Diabetes Reports, Vol. 17, No. 5, 34, 01.05.2017.

Research output: Contribution to journalReview article

@article{bb0daeb2294e4ef9bd81325f8626d5d9,
title = "Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice",
abstract = "Purpose of Review: This review provides an overview of the current state of drug therapy for obesity, with a focus on four new drug therapies—lorcaserin, phentermine/topiramate, naltrexone/bupropion, and liraglutide 3.0 mg—which have been approved by the US Food and Drug Administration (FDA) for long-term management of obesity since 2012. Topics discussed in this paper include rationale for pharmacotherapy, history of antiobesity drugs, and efficacy and safety data from randomized controlled trials with implications for clinical practice. Recent Findings: Weight loss achieved by currently approved drugs ranges from approximately 3 to 9{\%}, above and beyond weight loss with lifestyle counseling alone, after a year. Response and attrition rates in clinical trials indicate that the benefits of pharmacotherapy range from substantial for some patients, modest for others, and no benefits for others still. Summary: Decisions regarding selection of a suitable drug from the available pharmacotherapy options and duration of treatment should be based on the expected and observed benefit-to-risk balance and tailored to the needs of each individual patient using the principles of shared decision-making.",
keywords = "Antiobesity drugs, Obesity, Overweight, Pharmacologic treatment, Pharmacotherapy, Weight loss medications",
author = "Gadde, {Kishore M.} and Raj, {Y (Pritham)}",
year = "2017",
month = "5",
day = "1",
doi = "10.1007/s11892-017-0859-2",
language = "English (US)",
volume = "17",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Current Medicine Group",
number = "5",

}

TY - JOUR

T1 - Pharmacotherapy of Obesity

T2 - Clinical Trials to Clinical Practice

AU - Gadde, Kishore M.

AU - Raj, Y (Pritham)

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Purpose of Review: This review provides an overview of the current state of drug therapy for obesity, with a focus on four new drug therapies—lorcaserin, phentermine/topiramate, naltrexone/bupropion, and liraglutide 3.0 mg—which have been approved by the US Food and Drug Administration (FDA) for long-term management of obesity since 2012. Topics discussed in this paper include rationale for pharmacotherapy, history of antiobesity drugs, and efficacy and safety data from randomized controlled trials with implications for clinical practice. Recent Findings: Weight loss achieved by currently approved drugs ranges from approximately 3 to 9%, above and beyond weight loss with lifestyle counseling alone, after a year. Response and attrition rates in clinical trials indicate that the benefits of pharmacotherapy range from substantial for some patients, modest for others, and no benefits for others still. Summary: Decisions regarding selection of a suitable drug from the available pharmacotherapy options and duration of treatment should be based on the expected and observed benefit-to-risk balance and tailored to the needs of each individual patient using the principles of shared decision-making.

AB - Purpose of Review: This review provides an overview of the current state of drug therapy for obesity, with a focus on four new drug therapies—lorcaserin, phentermine/topiramate, naltrexone/bupropion, and liraglutide 3.0 mg—which have been approved by the US Food and Drug Administration (FDA) for long-term management of obesity since 2012. Topics discussed in this paper include rationale for pharmacotherapy, history of antiobesity drugs, and efficacy and safety data from randomized controlled trials with implications for clinical practice. Recent Findings: Weight loss achieved by currently approved drugs ranges from approximately 3 to 9%, above and beyond weight loss with lifestyle counseling alone, after a year. Response and attrition rates in clinical trials indicate that the benefits of pharmacotherapy range from substantial for some patients, modest for others, and no benefits for others still. Summary: Decisions regarding selection of a suitable drug from the available pharmacotherapy options and duration of treatment should be based on the expected and observed benefit-to-risk balance and tailored to the needs of each individual patient using the principles of shared decision-making.

KW - Antiobesity drugs

KW - Obesity

KW - Overweight

KW - Pharmacologic treatment

KW - Pharmacotherapy

KW - Weight loss medications

UR - http://www.scopus.com/inward/record.url?scp=85017189919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017189919&partnerID=8YFLogxK

U2 - 10.1007/s11892-017-0859-2

DO - 10.1007/s11892-017-0859-2

M3 - Review article

C2 - 28378293

AN - SCOPUS:85017189919

VL - 17

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 5

M1 - 34

ER -